Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma
Bianca M. Marin(Mayo Clinic), Jann N. Sarkaria(Mayo Clinic in Arizona), Jason E. Conage‐Pough(Massachusetts Institute of Technology), Katrina K. Bakken(Mayo Clinic in Arizona), Lihong He(Hospital of Stomatology, Sun Yat-sen University), Rachael A. Vaubel(Mayo Clinic), Ju‐Hee Oh(University of Minnesota), Minjee Kim(University of Minnesota), William F. Elmquist(University of Minnesota), Danielle M. Burgenske(Mayo Clinic in Arizona), Jeanette E. Eckel‐Passow(Mayo Clinic in Florida), Ian F. Parney(Mayo Clinic), Surabhi Talele(University of Minnesota), Shiv K. Gupta(Mayo Clinic), Brett L. Carlson(University of California, San Francisco), Nathalie Y.R. Agar(Texas Endosurgery Institute), Jennifer R. Cochran(Stanford University), Sylwia A. Stopka(Brigham and Women's Hospital), Paul A. Decker(University of California, San Francisco), Caterina Giannini(Mayo Clinic), Caitlyn L. Miller(Stanford University), Michael S. Regan(Brigham and Women's Hospital), Madison H. McMinn(Brigham and Women's Hospital), Sonia Jain(Mayo Clinic), Ann C. Mladek(Mayo Clinic), Gaspar J. Kitange(Hormel (United States)), Terence Burns(Mayo Clinic), Forest M. White(Center for Cancer Research), Shulan Tian(Mayo Clinic), Kendra A. Porath(Mayo Clinic)
Cited by 81
Related Papers
Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae
|Nature Biotechnology|2002|1.6k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
How many human proteoforms are there?
|Nature Chemical Biology|2018|945
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
|Nature Chemical Biology|2021|579